<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682860</url>
  </required_header>
  <id_info>
    <org_study_id>Çağdaş Yıldırım</org_study_id>
    <nct_id>NCT04682860</nct_id>
  </id_info>
  <brief_title>Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide</brief_title>
  <official_title>Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide: Randomized Double Blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara City Hospital Bilkent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ankara City Hospital Bilkent</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the most common complaints of admission to the emergency room is gastroenteritis. One&#xD;
      of the most common complaints in acute gastroenteritis is abdominal pain. The aim of our&#xD;
      study is to investigate whether hyoscine butylbromide used within the indication has an&#xD;
      effect on abdominal pain due to acute gastroenteritis. The main purpose of our study is to&#xD;
      reduce the pain of the patient at 30th and 60th minutes compared to 0th minute.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Change</measure>
    <time_frame>30 minute and1 hour</time_frame>
    <description>Pain change after intervention at 30th and 60th minute. Pain will assesed with Visual Analog Scale (100 mm). 13 mm of change at Visual Analog Scale will assesed as clinically significant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Gastroenteritis</condition>
  <condition>Abdominal Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the placebo arm, patients will be slowly injected with 2 ml of normal saline within 30 seconds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyoscine N butylbromide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the treatment arm, the patient will be injected intravenously with 1ml 20 mg of Hyoscine butylbromide and 1 ml of normal saline intravenously within 30 seconds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine N Butylbromide</intervention_name>
    <description>Hyoscine N butylbromide injection for the treatment of abdominal pain in acute gastroenteritis</description>
    <arm_group_label>Hyoscine N butylbromide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 ml of normal saline injection as placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with watery stools starting in the last 2 weeks and 3 times in 24 hours and&#xD;
             abdominal pain&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peritonitis&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to give consent&#xD;
&#xD;
          -  Medication given in the emergency room before being included in the study&#xD;
&#xD;
          -  Taking pain medication within 4 hours&#xD;
&#xD;
          -  Diabetes Mellitus and other neuropathic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Çağdaş Yıldırım, Ass. Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara City Hospital Bilkent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Çağdaş Yıldırım, Ass. Prof</last_name>
    <phone>00905057106614</phone>
    <email>cyildirim@ybu.edu.tr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alp Şener, Ass. Prof.</last_name>
    <phone>00905056497437</phone>
    <email>alpsener@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ankara City Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Çağdaş Yıldırım, Ass.Prof.</last_name>
      <phone>00905057106614</phone>
      <email>cyildirim@ybu.edu.tr</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Remington-Hobbs J, Petts G, Harris T. Emergency department management of undifferentiated abdominal pain with hyoscine butylbromide and paracetamol: a randomised control trial. Emerg Med J. 2012 Dec;29(12):989-94. doi: 10.1136/emermed-2011-200474. Epub 2012 Feb 3.</citation>
    <PMID>22307926</PMID>
  </reference>
  <reference>
    <citation>Arena C, Amoros JP, Vaillant V, Ambert-Balay K, Chikhi-Brachet R, Jourdan-Da Silva N, Varesi L, Arrighi J, Souty C, Blanchon T, Falchi A, Hanslik T. Acute diarrhea in adults consulting a general practitioner in France during winter: incidence, clinical characteristics, management and risk factors. BMC Infect Dis. 2014 Oct 30;14:574. doi: 10.1186/s12879-014-0574-4.</citation>
    <PMID>25358721</PMID>
  </reference>
  <reference>
    <citation>Shane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Kotloff K, Langley JM, Wanke C, Warren CA, Cheng AC, Cantey J, Pickering LK. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017 Nov 29;65(12):1963-1973. doi: 10.1093/cid/cix959.</citation>
    <PMID>29194529</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ankara City Hospital Bilkent</investigator_affiliation>
    <investigator_full_name>Cagdas Yildirim</investigator_full_name>
    <investigator_title>Ass. Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD maybe shared upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

